Ibiayi Dagogo-Jack
Distinguished in Squamous Cell Lung Carcinoma

Dr. Ibiayi Dagogo-Jack

Hematology Oncology | Oncology | Hematology
The General Hospital Corporation
55 Fruit St, 
Boston, MA 
Accepting New Patients
Offers Telehealth
Distinguished in Squamous Cell Lung Carcinoma
The General Hospital Corporation
55 Fruit St, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ibiayi Dagogo-Jack is a Hematologist Oncology specialist and an Oncologist in Boston, Massachusetts. Dr. Dagogo-Jack is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Lung Adenocarcinoma, and Tissue Biopsy. Dr. Dagogo-Jack is currently accepting new patients.

Her clinical research consists of co-authoring 98 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in MA
Hospital Affiliations
Martha's Vineyard Hospital Inc
Massachusetts General Hospital
Massachusetts Eye And Ear Infirmary -
North Shore Medical Center -
Wentworth-Douglass Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Martin's Point Generations
  • MEDICARE MAPD
  • OTHER MEDICARE
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

THE GENERAL HOSPITAL CORPORATION
55 Fruit St, Boston, MA 02114

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC
A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: September 25, 2025
Intervention Type: Drug
Study Drugs: Alectinib, Cobimetinib
Study Phase: Phase 1/Phase 2
An Open-label, Multi-center, Phase I Study of Oral IAG933 in Adult Patients With Advanced Mesothelioma and Other Solid Tumors
An Open-label, Multi-center, Phase I Study of Oral IAG933 in Adult Patients With Advanced Mesothelioma and Other Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2025
Intervention Type: Drug
Study Drug: IAG933
Study Phase: Phase 1
DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial
DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial
Enrollment Status: Completed
Publish Date: July 18, 2025
Intervention Type: Drug
Study Drug: Durvalumab
Study Phase: Phase 3
Phase 1 Safety Run-In and Phase 2 Randomized Clinical Trial of Anetumab Ravtansine and Pembrolizumab (MK-3475) Compared to Pembrolizumab Alone for Mesothelin-Positive Malignant Pleural Mesothelioma
Phase 1 Safety Run-In and Phase 2 Randomized Clinical Trial of Anetumab Ravtansine and Pembrolizumab (MK-3475) Compared to Pembrolizumab Alone for Mesothelin-Positive Malignant Pleural Mesothelioma
Enrollment Status: Active_not_recruiting
Publish Date: October 16, 2024
Intervention Type: Biological, Other
Study Drugs: Anetumab Ravtansine, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: September 21, 2022
Intervention Type: Drug, Dietary supplement, Biological
Study Drugs: Telaglenastat, Carboplatin Chemotherapy, Pemetrexed Chemotherapy, Pembrolizumab Immunotherapy, Dexamethasone
Study Phase: Phase 2
View 4 Less Clinical Trials

94 Total Publications

Treatment of Pleural Mesothelioma: ASCO Guideline Clinical Insights.
Treatment of Pleural Mesothelioma: ASCO Guideline Clinical Insights.
Journal: JCO oncology practice
Published: March 07, 2025
Similar Doctors
Elite in Squamous Cell Lung Carcinoma
Dr. Peter S. Hammerman
Oncology
Elite in Squamous Cell Lung Carcinoma
Dr. Peter S. Hammerman
Oncology
450 Brookline Ave, Dana Farber Cancer Institute, 
Boston, MA 
 (2.7 miles away)
617-632-3000
Languages Spoken:
English

Peter Hammerman is an Oncologist in Boston, Massachusetts. Dr. Hammerman is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. His top areas of expertise are Squamous Cell Lung Carcinoma, Lung Adenocarcinoma, Lung Cancer, and Non-Small Cell Lung Cancer (NSCLC).

Distinguished in Squamous Cell Lung Carcinoma
Dr. J P. Marcoux
Hematology Oncology | Oncology | Hematology
Distinguished in Squamous Cell Lung Carcinoma
Dr. J P. Marcoux
Hematology Oncology | Oncology | Hematology

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave, 
Boston, MA 
 (2.7 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

J Marcoux is a Hematologist Oncology specialist and an Oncologist in Boston, Massachusetts. Dr. Marcoux is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and EGFR Positive Lung Cancer. Dr. Marcoux is currently accepting new patients.

Distinguished in Squamous Cell Lung Carcinoma
Dr. Jacob M. Sands
Hematology Oncology | Oncology | Hematology
Distinguished in Squamous Cell Lung Carcinoma
Dr. Jacob M. Sands
Hematology Oncology | Oncology | Hematology

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave, 
Boston, MA 
 (2.7 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jacob Sands is a Hematologist Oncology specialist and an Oncologist in Boston, Massachusetts. Dr. Sands is rated as an Elite provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Lung Adenocarcinoma. Dr. Sands is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dagogo-Jack's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 13 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile